Strategic position Clinical-stage biotechnology company focusing on dual-targeted radiopharmaceutical therapies for cancer, suggesting collaboration opportunities with pharma players seeking next-generation oncology platforms and combination strategies.

Recent validated data Positive Phase 2 results for CONV01-α in lu-psma-exposed metastatic castration-resistant prostate cancer presented at ASCO 2026, indicating a potentially addressable market and validating the platform for discussions with oncology investors and licensing partners.

Leadership growth New Chief Business and Strategy Officer joined in April 2026 and expanded leadership including CSO and CFO since 2023, signaling readiness for business development, partnerships, and scale-up conversations with potential collaborators.

Financing runway Funding to date around $152 million with ongoing VC support and a recent $22.2 million financing round, implying a solid but scalable budget window for co-development, phase advancement, and strategic licensing deals.

Market expansion Focus on radiopharmaceuticals for prostate cancer and other cancers positions opportunities in Genitourinary and broader oncology collaborations, including potential OEM or co-development agreements with larger biopharma seeking novel radioligand platforms.